SCHEMBL3574516

SCHEMBL3574516

Nc1ccc(Cc2ccc3c(c2)CC(=O)N3)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.50
SMYD3 Q9H7B4 2/20 0.47
MAOB P27338 3/20 0.47
GRIA1 P42261 2/20 0.46
CACNG8 Q8WXS5 2/20 0.46
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
TDP2 O95551 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP3A4 P08684 1/20 0.44
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PDK2 Q15119 1/20 0.43
EPHX2 P34913 1/20 0.43
PGR P06401 1/20 0.42
CRBN Q96SW2 1/20 0.42
HDAC3 O15379 1/20 0.41
CA9 Q16790 1/20 0.41
HTR1A P08908 1/20 0.41
DRD2 P14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3570265 0.87 GRIA1 (0.49) AHRSMYD3MAOBGRIA1CACNG8
SCHEMBL6904021 0.86 AHR (0.53) AHRSMYD3MAOBGRIA1CACNG8
SCHEMBL3574515 0.82 SMYD3 (0.49) AHRSMYD3MAOBEPHX2HDAC3
SCHEMBL28118843 0.81 MAOB (0.65) AHRMAOBCRBN
SCHEMBL22660 0.81 AHR (0.61) AHRSMYD3GRIA1CACNG8PDE3B
SCHEMBL15941764 0.81 SMYD3 (0.55) AHRSMYD3MAOBGRIA1CACNG8
SCHEMBL10711906 0.80 PDE3B (0.68) AHRGRIA1CACNG8PDE3BPDE3A
SCHEMBL260951 0.80 AHR (0.56) AHRSMYD3MAOBGRIA1CACNG8
SCHEMBL30946048 0.80 MAOB (0.56) AHRSMYD3MAOBGRIA1CACNG8
Hydrochloric Acid SCHEMBL15206761 0.80 AHR (0.59) AHRSMYD3GRIA1CACNG8PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7749530-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-07-06 US disclosed
WO-2010075197-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2010-07-01 WO disclosed
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US disclosed
US-20090208557-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-20 US disclosed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US disclosed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208557-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 AHR 2818/4885SMYD3 3186/4885MAOB 971/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 AHR 2478/4885SMYD3 1968/4885MAOB 1262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.